ArriVent BioPharma (AVBP) Proxy filing summary

Executive summary

• The 2026 annual meeting will be held virtually on June 18, 2026, with voting available online, by phone, or by mail.

• Stockholders will vote on electing three directors and ratifying PricewaterhouseCoopers LLP as the independent auditor for 2026.

• Proxy materials are primarily distributed electronically to reduce costs and environmental impact.

• Only holders of record as of April 21, 2026, may vote; 46,368,442 shares are outstanding.

Voting matters and shareholder proposals

• Three directors are nominated for election to serve until 2029: James Healy, John Hohneker, and Stuart Lutzker.

• Stockholders are asked to ratify PricewaterhouseCoopers LLP as the independent auditor for 2026.

• Board recommends voting FOR all director nominees and auditor ratification.

• Shareholder proposals and director nominations for 2027 must be submitted 90–120 days before the next annual meeting anniversary.

Board of directors and corporate governance

• The board consists of seven members divided into three classes, with staggered three-year terms.

• Five directors are independent under Nasdaq rules; two are executive officers.

• Board committees include audit, compensation, and nominating/governance, each with independent members and defined charters.

• Lead Independent Director role established to enhance governance and board effectiveness.

• Board and committees met regularly in 2025, with high attendance.